NAD+ / NMN / NR: The Complete Guide

Overview

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It is required for hundreds of metabolic reactions — from converting food into energy to repairing damaged DNA. NAD+ also activates sirtuins, a family of seven enzymes that regulate cellular stress responses, inflammation, and gene expression. Without adequate NAD+, cells cannot perform basic maintenance functions, and the molecular machinery of aging accelerates.

NAD+ levels decline with age. Studies measuring NAD+ in human tissues have documented reductions of approximately 50% between young adulthood and middle age in some compartments (Yoshino et al., 2011). This decline is driven by increased activity of NAD+-consuming enzymes — particularly CD38 (an ectoenzyme that degrades NAD+ and rises with chronic inflammation) and PARPs (poly-ADP-ribose polymerases that consume NAD+ during DNA repair). Simultaneously, the biosynthetic capacity to produce NAD+ diminishes.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — molecules the body converts into NAD+. Both have been shown to raise NAD+ levels in animal models and human studies. They represent the two most-studied oral strategies for NAD+ restoration and form the biochemical foundation of a significant portion of the consumer longevity supplement market.

The field is closely associated with David Sinclair, professor of genetics at Harvard Medical School, whose laboratory has produced foundational research on sirtuins and NAD+ biology. Sinclair is also co-founder of multiple companies commercializing NAD+-related products and therapies — a dual role that has generated both scientific advancement and scrutiny regarding conflicts of interest.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

NAD+ in Cellular Metabolism

NAD+ participates in redox reactions throughout the cell, shuttling electrons in the mitochondrial electron transport chain (oxidative phosphorylation), glycolysis, and the citric acid cycle. In its oxidized form (NAD+), it accepts electrons; in its reduced form (NADH), it donates them. This cycling is the foundation of cellular energy production — without it, ATP synthesis halts.

Sirtuins: The NAD+-Dependent Regulators

Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent deacylases and ADP-ribosyltransferases. They remove acetyl groups from histone and non-histone proteins, regulating gene expression, mitochondrial biogenesis, inflammation, and cellular stress responses. Critically, sirtuins consume NAD+ as a substrate — they do not merely bind it. This means sirtuin activity is directly limited by NAD+ availability (Yoshino et al., 2011).

• SIRT1: Nuclear sirtuin; regulates inflammation (NF-κB), fat metabolism (PPARγ), and mitochondrial biogenesis (PGC-1α). The primary target of resveratrol research.
• SIRT3: Mitochondrial sirtuin; regulates oxidative phosphorylation and reactive oxygen species (ROS) detoxification.
• SIRT6: Involved in DNA double-strand break repair and telomere maintenance.

PARP: The NAD+ Consumer

Poly-ADP-ribose polymerases (PARPs) are DNA repair enzymes that consume large quantities of NAD+ when activated. PARP1 is activated by DNA damage — which accumulates with age and environmental exposure. As DNA damage increases, PARPs consume more NAD+, creating a competitive drain on the same NAD+ pool that sirtuins require. This creates a metabolic conflict: the more DNA damage a cell sustains, the less NAD+ remains available for sirtuin-mediated protective functions (Imai and Guarente, 2014).

CD38: The Age-Related NAD+ Destroyer

CD38 is an ectoenzyme expressed on immune cells and other tissues. Its primary function involves calcium signaling, but it also degrades NAD+ and its precursors with high efficiency. CD38 expression increases with age and chronic inflammation — and this increase has been identified as a major driver of age-related NAD+ decline. Studies in CD38-knockout mice show preserved NAD+ levels with aging (Camacho-Pereira et al., 2016). CD38 inhibitors (such as apigenin and 78c) are under investigation as a complementary strategy to NAD+ precursor supplementation.

The NAD+ Biosynthesis Pathway

NAD+ is synthesized through three pathways:

• De novo pathway: From tryptophan (an essential amino acid). Slow and inefficient in most tissues.
• Preiss-Handler pathway: From nicotinic acid (niacin / vitamin B3). The classic niacin pathway.
• Salvage pathway: From nicotinamide (NAM), NR, or NMN. This is the primary pathway for NAD+ recycling and the pathway that NMN and NR supplementation feeds into. NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2), and NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1/2/3).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Foundational Animal Studies

• Yoshino et al. (2011): Demonstrated that NMN administration restored NAD+ levels in diabetic mice and improved glucose tolerance, insulin sensitivity, and lipid metabolism. This was one of the first studies to propose NAD+ decline as a causal factor in metabolic disease and NMN supplementation as a therapeutic strategy (PubMed).
• Mills et al. (2016): Long-term NMN administration (12 months) in aging mice suppressed age-related weight gain, improved insulin sensitivity, enhanced physical activity, improved lipid profiles, and preserved gene expression patterns in a tissue-specific manner. This study provided the first evidence that chronic NMN supplementation could mitigate multiple hallmarks of aging simultaneously in mammals (PubMed).
• de Picciotto et al. (2016): NMN supplementation reversed age-related arterial dysfunction in old mice, improving endothelium-dependent dilation and reducing aortic stiffness. The effect was mediated through restored SIRT1 activity and reduced oxidative stress (PubMed).

Human Clinical Trials

• Martens et al. (2018): A randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults. NR supplementation (1,000 mg/day for 6 weeks) raised blood NAD+ metabolites by approximately 60% and showed trends toward reduced systolic blood pressure and aortic stiffness, though these did not reach statistical significance in this small trial (n=24) (PubMed).
• Yi et al. (2023): A randomized, double-blind, placebo-controlled trial of NMN in middle-aged adults. NMN supplementation (600 mg/day or 1,200 mg/day for 60 days) significantly increased blood NAD+ levels, improved 6-minute walking distance, and reduced biological age as measured by blood biomarkers. This represented one of the first human RCTs to demonstrate functional improvements from NMN (PubMed).
• Yoshino et al. (2021): NMN (250 mg/day for 10 weeks) in postmenopausal women with prediabetes improved skeletal muscle insulin sensitivity and signaling but did not significantly alter overall glucose tolerance or body composition (PubMed).

Limitations of Current Evidence

• No hard clinical endpoints: No human trial has demonstrated that NAD+ precursors reduce disease incidence, prevent cardiovascular events, or extend lifespan.
• Small sample sizes: Most human trials have enrolled fewer than 50 participants.
• Short duration: Human studies have run 6–12 weeks; aging is a decades-long process.
• Surrogate markers: Most studies measure NAD+ levels or metabolic biomarkers rather than clinical outcomes.
• Bioavailability questions: Whether oral NMN reaches target tissues efficiently in humans is still debated; NMN may be partially degraded to nicotinamide in the gut before absorption.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

NMN vs. NR

The Debate

Proponents of NMN argue that it is "one step closer" to NAD+ in the biosynthetic pathway and therefore more efficient. Proponents of NR point to its established human safety data, regulatory status, and the evidence that NMN may be partially converted to NR before gut absorption anyway — making the "one step closer" argument potentially moot.

The practical reality: both molecules raise NAD+ in humans. No head-to-head human comparison has been published. NR has the regulatory advantage of legal OTC supplement status. NMN has a larger consumer following, partly driven by Sinclair's public advocacy. From a biochemical standpoint, the difference may be smaller than the marketing suggests.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

NMN Dosing Protocols

Sources: Yi et al., 2023 — NMN efficacy and safety in human clinical trials · Katayoshi et al., 2024 — Safety and efficacy of long-term NMN supplementation

NR Dosing Protocols

Sources: Martens et al., 2018 — Chronic NR supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults · Lapatto et al., 2023 — NR-SAFE: high-dose nicotinamide riboside safety trial

Administration

Administration: Both NMN and NR are taken orally, typically in capsule form. Morning administration is commonly recommended based on the rationale that NAD+ supports circadian rhythm function and daytime metabolic activity. NMN is also available in sublingual powder form; the clinical significance of sublingual versus swallowed delivery has not been established in controlled trials.

Storage

• NMN: Store in a cool, dry place. Some manufacturers recommend refrigeration to slow degradation. Avoid heat and moisture exposure.
• NR (Niagen): Store at room temperature per label instructions. Stable in standard supplement capsule formulations.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Timeline

Sources: Yi et al., 2023 — NMN efficacy and safety, 6-min walking distance (GeroScience) · Martens et al., 2018 — Chronic NR supplementation in older adults (Nature Communications) · Kim et al., 2024 — NMN ingestion and blood NAD+ levels

What the Clinical Data Shows

In the Yi 2023 trial, NMN supplementation improved 6-minute walking distance — an objective measure of physical function — and reduced biological age markers. The Martens 2018 NR trial showed trends toward cardiovascular improvement but did not achieve statistical significance for most endpoints. Neither trial measured subjective quality-of-life endpoints comprehensively.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Theoretical Concerns

• Cancer risk: NAD+ is required by all rapidly dividing cells, including cancer cells. Theoretically, raising NAD+ could support tumor metabolism. No clinical evidence supports increased cancer risk from NMN/NR supplementation at studied doses, but long-term surveillance data does not exist. Individuals with active cancer should consult their oncologist.
• Methylation drain: NAD+ metabolism generates nicotinamide (NAM), which is methylated for excretion. High-dose NAD+ precursor supplementation could theoretically deplete methyl donors (SAMe, folate). Some practitioners recommend concurrent trimethylglycine (TMG) supplementation to offset this, though clinical evidence for this practice is limited.
• Long-term effects: No human safety data beyond 12 weeks of continuous use exists from controlled trials.

Contraindications

• Active cancer or recent cancer treatment — theoretical concern regarding NAD+ support of tumor metabolism
• Pregnancy and breastfeeding — no safety data
• Gout — NAD+ metabolism may elevate uric acid in susceptible individuals

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

NMN: The FDA Decision

In November 2022, the FDA determined that NMN could not be marketed as a dietary supplement. The basis for this decision was that NMN was the subject of substantial clinical investigations as a new drug — specifically, Metro International Biotech (a company co-founded by David Sinclair) had filed an IND application for NMN-based therapies. Under the Federal Food, Drug, and Cosmetic Act, once a substance is authorized for investigation as a new drug, it generally cannot be marketed as a dietary supplement unless it was previously marketed as a supplement before the IND was filed.

The Natural Products Association and several NMN supplement manufacturers challenged this decision. As of early 2026, the legal landscape remains unsettled:

• NMN continues to be widely sold online, often labeled as a "research compound" or through international sellers.
• The FDA has not taken widespread enforcement action against NMN sellers.
• Legislative efforts to restore NMN's supplement status have been introduced in Congress but not passed.
• The practical result is a gray market: NMN is available but lacks the regulatory protections (cGMP manufacturing standards, labeling requirements) that apply to recognized dietary supplements.

NR: Supplement Status

NR (as Niagen, ChromaDex's patented form) has GRAS (Generally Recognized as Safe) status, granted through FDA's notification process. It is legally marketed and sold as a dietary supplement in the United States. NR is subject to standard dietary supplement regulations including cGMP manufacturing requirements and labeling standards. Generic NR products are also available.

NAD+ IV Infusions

NAD+ administered intravenously in clinical settings occupies a different regulatory space — it is typically compounded by pharmacies for provider-prescribed use. IV NAD+ clinics have expanded significantly, particularly in longevity and addiction treatment settings. The evidence base for IV NAD+ is substantially smaller than for oral NMN or NR.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Insurance

NAD+ precursors (NMN, NR) are not covered by any insurance plan. They are classified as dietary supplements or research compounds — not prescription medications — for purposes of insurance reimbursement. NAD+ IV infusions are similarly not covered.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Conflicts of Interest

David Sinclair

David Sinclair, PhD, is Paul F. Glenn Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His laboratory has produced foundational work on sirtuins, NAD+ biology, and epigenetic reprogramming. He is also:

• Co-founder of Metro International Biotech — the company whose IND application for NMN led to the FDA's removal of NMN from the dietary supplement pathway. Metro is developing NMN as a pharmaceutical drug.
• Co-founder or advisor to multiple biotech companies focused on aging, including Life Biosciences, Iduna Therapeutics, Jumpstart Fertility, Animal Biosciences, and others.
• Author of Lifespan: Why We Age — and Why We Don't Have To (2019), a bestselling book that popularized NAD+ supplementation and sirtuin biology to a consumer audience.
• Public advocate for NMN supplementation — Sinclair has publicly disclosed his personal NMN supplementation regimen, contributing significantly to consumer demand for NMN products.

Sinclair's dual role has drawn scrutiny from peers and science journalists. Key concerns include:

• Financial incentive alignment: Sinclair's companies benefit financially from increased public interest in NAD+ biology and supplementation. His public advocacy for NMN — while consistent with his published research — also serves commercial interests.
• Regulatory impact: Metro International Biotech's IND filing for NMN directly triggered the FDA's removal of NMN from the supplement market — potentially creating a future pharmaceutical monopoly on a compound that was previously available as an inexpensive supplement.
• Replication concerns: Some of Sinclair's earlier work on resveratrol and SIRT1 activation has faced replication challenges from independent laboratories (see Resveratrol article).
• Disclosure: Sinclair does disclose his conflicts of interest in published papers and public appearances. The question is whether the general public adequately weighs these disclosures when evaluating his claims.

ChromaDex and NR

ChromaDex, Inc. (NASDAQ: CDXC) holds key patents on Niagen (NR chloride) and licenses NR to supplement brands. ChromaDex has funded or co-funded several NR human trials. This is common in the supplement industry — but it means that much of the NR human data has been produced with industry involvement. Independent replication by academic groups without industry funding is more limited.

How to Evaluate Claims

Conflicts of interest do not automatically invalidate research. The presence of a conflict means the research should be evaluated with additional scrutiny — particularly regarding study design, endpoint selection, and interpretation of results. When evaluating NAD+ claims:

• Look for peer-reviewed publications in established journals.
• Check whether the study was independently funded or industry-funded.
• Evaluate whether the study measured hard clinical endpoints (disease outcomes, mortality) or surrogate biomarkers (NAD+ levels, gene expression).
• Consider whether the findings have been replicated by independent laboratories.
• Be cautious of claims extrapolated from animal data to human benefit without human trial support.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

• NAD+ is essential for cellular function and declines with age. This decline is driven by increased CD38 and PARP activity and reduced biosynthesis. Lower NAD+ compromises sirtuin activity, DNA repair, and mitochondrial function.
• NMN and NR are the two primary oral NAD+ precursors. Both raise NAD+ levels in humans. No head-to-head human trial has determined which is superior for clinical outcomes.
• Animal data is strong. NMN supplementation in mice (Mills 2016) improved metabolic health, physical activity, insulin sensitivity, and gene expression across multiple tissues.
• Human data is early but promising. NR raises NAD+ ~60% (Martens 2018). NMN improves walking endurance and biological age markers (Yi 2023). No hard clinical endpoints (disease prevention, lifespan) have been demonstrated.
• NMN has been removed from the dietary supplement pathway by the FDA (Nov 2022) due to an IND filing by Metro International Biotech, co-founded by David Sinclair. NR remains a legal OTC supplement with GRAS status.
• Conflicts of interest are significant in this field. Key researchers hold financial positions in companies that benefit from public interest in NAD+ supplementation. This does not invalidate the research but warrants awareness.
• Cost is $40–$150/month for oral NMN or NR. Not covered by insurance.
• Side effects are generally mild: GI discomfort, flushing, headache. Long-term safety data beyond 12 weeks is absent from controlled trials.

Sources & Further Reading

NAD+ Biology & Mechanism

• Yoshino J, Mills KF, Yoon MJ, Imai S (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4):528-536.
• Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8):464-471.
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6):1127-1139.

Animal Studies

• Mills KF, Yoshida S, Stein LR, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6):795-806.
• de Picciotto NE, Gano LB, Johnson LC, et al. (2016). Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell, 15(3):522-530.

Human Clinical Trials

• Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1):1286.
• Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1):29-43.
• Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547):1224-1229.

Regulatory

• FDA: Nicotinamide Mononucleotide (NMN) — Dietary Supplement Ingredient Directory
• FDA: GRAS Notices (NR/Niagen)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.